Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients
NCT ID: NCT07126106
Last Updated: 2025-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
55 participants
OBSERVATIONAL
2025-02-01
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)
NCT06167083
Prognostic Value of the CALLY Index in Patients With Sepsis
NCT07285499
Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey
NCT07300306
Can Shock Indices Be Prognostic Indicators in Sepsis/Septic Shock?
NCT06415006
The Early Prediction of Sepsis in ICU
NCT05088850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In recent years, machine learning-based prediction models have been increasingly used as decision support tools in healthcare. The GRADY prediction models, developed retrospectively in our hospital, aim to predict the risk of sepsis due to gram-negative bacteremia using vital signs and laboratory parameters obtained during routine clinical monitoring. However, prospective validation of these models is essential prior to their integration into clinical practice.
The rationale of this study is to facilitate early identification of ICU patients at risk for bacteremia or sepsis to enable prompt initiation of treatment. Reducing mortality and morbidity through early detection may help alleviate the burden on healthcare systems. Moreover, supporting current clinical practices with early prediction models may enhance decision-making efficiency. The use of early warning systems and machine learning-based algorithms may improve clinical predictive power and allow for timely interventions by clinicians. This study aims to evaluate the diagnostic accuracy and clinical applicability of GRADY models through prospective validation. In this regard, the findings may contribute to the development of new approaches for sepsis and bacteremia management in critical care settings.
In current clinical practice, scoring systems such as the Sequential Organ Failure Assessment (SOFA), Systemic Inflammatory Response Syndrome (SIRS), and National Early Warning Score 2 (NEWS2) are used to define sepsis and to identify high-risk patients early. However, these scoring systems are based on a limited set of clinical and laboratory parameters and have shown suboptimal sensitivity and specificity in early sepsis diagnosis according to various studies. This limitation may reduce the chance of early intervention and negatively affect patient outcomes. GRADY models aim to offer risk prediction based on routinely collected clinical and laboratory data using machine learning algorithms, providing an alternative to conventional scoring systems. This study will compare the diagnostic accuracy and clinical performance of GRADY models with widely used scoring systems such as SOFA, SIRS, and NEWS2.
Currently, there are only a limited number of validated and widely accepted scoring systems available for the early identification of bacteremia. The Pitt Bacteremia Score was developed to predict short-term mortality in patients diagnosed with bacteremia and has been validated in several studies. Unlike the Pitt score, GRADY models aim to predict the risk of bacteremia and sepsis in the early period before diagnosis using routine clinical and laboratory data. Although the two systems do not serve exactly the same purpose, Pitt Bacteremia Scores will be calculated for all patients in this study, and the potential relationship with high-risk classification by the GRADY model will be evaluated statistically.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ICU stay of 48 hours or longer
* Patients from whom blood cultures were obtained during routine monitoring
* Signed informed consent form
Exclusion Criteria
* ICU stay shorter than 48 hours
* Patients without blood cultures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sisli Hamidiye Etfal Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AHMET DOGUKAN
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sisli etfal research and training hospital
Seyrantepe, Istanbul, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
dogu-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.